Overview

Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2 Positive Operable Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

At present, trastuzumab combined with patuzumab has become the standard neoadjuvant therapy for high-risk HER2 positive breast cancer. TCbHP has been the standard choice of neoadjuvant therapy for HER2 positive breast cancer patients with early high-risk or locally advanced HER2 positive breast cancer. Whether nab-PHP can achieve the same effect as TCbHP is still uncertain.

Phase:

Phase 3

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Carboplatin
Docetaxel
Paclitaxel
Trastuzumab